
Marni J. Falk, M.D., is the director of the Mitochondrial-Genetics Clinic at The Children’s Hospital of Philadelphia.
CREDIT
The Children’s Hospital of Philadelphia
Social and ethical issues arise beyond potential for preventing rare complex diseases
Sophisticated prenatal techniques, not yet in clinical practice, offer the potential to prevent a cruel multi-system genetic disease passing from mother to child long before birth.
But these emerging tools raise important questions: might there be unintended, even irreversible risks to the resulting child–or even that child’s future descendants? Are there potential risks to the mother’s health? What about other potential consequences if its use is broadened to include indications beyond strict disease prevention, such as adapting the tools into conception aids for older women?
The tools in question, mitochondrial replacement techniques (MRTs), aim to prevent mother-to-child transmission of mitochondrial DNA disease –a complex set of rare disorders caused by defective DNA within the mitochondria, the tiny energy-producing structures existing outside the nucleus of cells. Such disease may present at any age or level of severity, attacking a combination of organs and systems, often fatally. There are no current cures or approved therapies for any of these disorders, which clinicians manage by treating the diverse symptoms that may progressively affect each patient.
Earlier this month, an expert panel of national experts formed by the Institute of Medicine at the request of the U.S. Food and Drug Administration (FDA) recommended that research into MRTs should proceed under carefully proscribed guidelines.
Three members of that panel co-authored a Perspective article in today’s New England Journal of Medicine on MRT’s implications for clinicians. The article begins, “Mitochondrial DNA (mtDNA) disease may be the poster child for highly targeted, ‘personalized’ medicine.”
“Even though MRTs would not confer health benefits on patients who already have mitochondrial DNA diseases, many patients with a known risk for transmitting such a disease to their offspring are highly motivated to prevent that from occurring,” said Marni J. Falk, M.D., director of the Mitochondrial-Genetics Clinic at The Children’s Hospital of Philadelphia and first author of the article. “That motivation is clear when we counsel patients and families affected by mtDNA disease, and recent patient surveys have reinforced that preventing disease transmission is a prevailing concern in this population.”
Falk’s co-authors are Jeffrey Kahn, Ph.D., M.P.H., of the Johns Hopkins Berman Institute of Bioethics, and Alan Decherney, M.D., an obstetrician-gynecologist and reproductive endocrinologist at the National Institute of Child Health and Human Development.
Kahn chaired the Institute of Medicine expert panel.
Because the expert panel stated that the child’s safety was paramount, it recommended that MRTs should initially be studied only in male embryos, since males do not transmit mitochondrial DNA to their children. The panel further argued that the FDA should make clear policy and that professional societies should issue practice recommendations to limit future MRT usage to appropriate patients.
The authors repeat the panel’s stipulation that children conceived after MRT should be monitored long-term, “probably well into adulthood,” much longer than is done after in vitro fertilization with pre-implantation diagnosis for diseases based in nuclear DNA.
Finally, because MRTs require mixing mitochondrial DNA from a female donor with DNA from the nucleus of the mother and father, the authors note that researchers should investigate unanticipated health problems and possibly questions about identity, before regulatory approval or clinical use can occur for the techniques.
Learn more: What will emerging genetic tools for mitochondrial DNA replacement mean for patients?
The Latest on: Mitochondrial DNA replacement
[google_news title=”” keyword=”mitochondrial DNA replacement” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Mitochondrial DNA replacement
- Mitochondrial dysfunction and genetic variations in neuro-ophthalmology diseaseson November 29, 2023 at 6:30 pm
The mitochondrion plays a pivotal role in cellular energy production, orchestrated by the oxidative phosphorylation (OXPHOS) machinery governed by nuclear genes and the circular double-stranded ...
- Remains of Indiana soldier found in burned-out tank in Germany are finally identified nearly EIGHT DECADES after he was killed in WWII battleon November 24, 2023 at 7:37 am
A soldier from Indiana killed during battle in Germany during World War II has been identified 79 years after his death. U.S. Army 2nd Lt. Gene F. Walker of Richmond, Indiana, has been named by ...
- News tagged with mitochondrial dnaon November 12, 2023 at 3:59 pm
Mitochondrial DNA (mtDNA) is the DNA located in organelles called mitochondria. Most other DNA present in eukaryotic organisms is found in the cell nucleus. Mitochondrial DNA was discovered by ...
- Zen and the art of mitochondrial maintenance: The machinery of death makes a healthier lifeon November 7, 2023 at 4:00 pm
The researchers found that enzymes responsible for killing cells are also required to remove damaged mitochondrial DNA. In the absence of these enzymes, defective mitochondria pile up. Rothman and ...
- REPLI-g Mitochondrial DNA Kiton October 30, 2023 at 1:06 pm
REPLI-g Mitochondrial DNA Kit은/는 분자생물학 분야에 사용하기 위한 것입니다. 이 제품은 질병의 진단, 예방, 또는 치료용이 아닙니다.
- Mitochondrial DNA Copy Number and Incident Heart Failureon October 26, 2023 at 7:55 am
It is thus critical to identify novel risk factors for developing HF. Mitochondrial DNA copy number (mtDNA-CN), an indirect biomarker of mitochondrial dysfunction, is associated with atherosclerotic ...
- A Boy With Muscle Weakness, Hypercarbia, and the Mitochondrial DNA A3243G Mutationon October 22, 2023 at 5:00 pm
The point mutation in the mitochondrial genome tRNALeu (A3243G) is associated with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS). We report a ...
- Mitochondrial enteropathy: the primary pathology may not be within the gastrointestinal tracton September 12, 2023 at 4:54 pm
BACKGROUND Mitochondrial DNA (mtDNA) defects are an important cause of disease. Although gastrointestinal symptoms are common in these patients, their pathogenesis remains uncertain. AIM To ...
via Bing News